Affected by abrupt temperature changes and environmental factors in autumn and winter, individuals often experience upper respiratory tract-related symptoms such as fever, cough, nasal congestion, and sore throat. When multiple symptoms occur concurrently, they are collectively referred to in medicine as "respiratory syndrome."
The core cause of its onset is closely related to the impaired defense function of the respiratory mucosa. The main factor lies in the invasion of the respiratory tract by pathogens such as viruses, bacteria, mycoplasma, and chlamydia during the high-incidence period of infections. These pathogens adhere to mucosal epithelial cells, triggering local inflammatory responses, which in turn lead to symptoms like cough and sputum production. High-risk groups include immunocompromised individuals, people with allergic constitutions, those with long-term exposure to high-risk environments, and individuals with poor living habits.
For respiratory syndrome caused by infectious factors, the primary transmission route is droplet transmission, and its clinical manifestations include upper respiratory tract infections and lower respiratory tract infections.
iGeneTech's Respiratory Syndrome Pathogenic Microorganism Identification Panels
Based on its independently developed TargetSeq® liquid-phase hybridization capture sequencing technology, iGeneTech has launched over 40 identification Panels for common respiratory syndrome pathogenic microorganisms, with reference to multiple strain sequences included in the NCBI database.
Among them, probes for 25 types of bacteria and fungi are designed following the principle of "intra-species conservation and inter-species specificity," while probes for 13 types of viruses adopt a full-length coverage design. A total of more than 150,000 probes have been developed, covering 38 common respiratory pathogens. These Panels can enhance the monitoring of respiratory pathogen spectra in populations, provide important support for epidemic trend assessment, early outbreak identification, and risk analysis, and meet the needs of routine prevention and control work of disease control and prevention departments.
Table 1. Bacteria Involved in Diagnosis and Treatment of ABX Infectious Diseases | |||||
Acinetobacter baumannii | Actinomycete | Aeromonas | Bacillus | Bacteroides fragilis | Bacteroides |
Bartonella | Bordetella | Borrelia | Brucella | Burkholderia cepacia complex | Burkholderia mallei |
Campylobacter | Campylobacter jejuni | Capnocytophaga canimorsus | Chlamydia trachomatis | Chlamydia pneumoniae | Chlamydia psittaci |
Citrobacter | Clostridium botulinum | Clostridium difficile | Clostridium | Clostridium tetani | Corynebacterium diphtheriae |
Coxiella burnetii | Ehrlichia | Eikenella corrodens | Enterobacter | Enterococcus | Erysipelothrix rhusiopathiae |
Escherichia coli | Francisella tularensis | Haemophilus ducreyi | Haemophilus influenzae | Moraxella catarrhalis | Klebsiella
|
Lactobacillus | Legionella | Leptospira | Listeria monocytogenes | Morganella | Mycobacterium abscessus |
Mycobacterium avium Complex | Mycobacterium chelonae | Mycobacterium fortuitum | Mycobacterium kansasii | Mycobacterium leprae | Mycobacterium marinum |
Mycoplasma pneumoniae | Neisseria gonorrhoeae | Neisseria meningitidis | Nocardia | Pasteurella multocida | Peptostreptococcus |
Plesiomonas | Propionibacterium | Proteus | Providencia | Pseudomonas aeruginosa | Rhodococcus equi |
Rickettsia rickettsii | Rickettsia | Salmonella | Shigella dysenteriae | Shigella | Staphylococcus |
Staphylococcus aureus | Stenotrophomonas maltophilia | Streptococcus moniliformis | Streptococcus pneumoniae | Streptococcus pyogenes | Streptococcus |
Treponema pallidum | Tropheryma whipplei | Vibrio cholerae | Vibrio | Yersinia pestis | Yersinia |
Table 2. Fungi Involved in Diagnosis and Treatment of ABX Infectious Diseases | |||||
Aspergillus | Blastomyces dermatitidis | Candida albicans | Candida | Coccidioides immitis | Cryptococcus neoformans |
Dermatophyte | Fusarium | Histoplasma capsulatum | Scedosporium boydii | Sporothrix schenckii | |
Table 3. Viruses Involved in Diagnosis and Treatment of ABX Infectious Diseases | |||
Mastadenovirus | Cytomegalovirus | Enterovirus | Epstein-Barr virus |
Hantaviridae | Hepatitis A virus | Hepatitis B virus | Hepacivirus hominis |
Herpes simplex virus | human gammaherpesvirus 8 | Hepatitis D virus | human Papillomavirus |
JC virus × BK virus | Measles morbillivirus | Molluscum contagiosum virus | Mumps orthorubulavirus |
Norovirus | Respirovirus | Human parvovirus B19 | Lyssavirus |
Human respiratory syncytial virus | Rhinovirus | Rubella virus | Zoster virus |
West Nile virus | Human T- lymphotropic virus (HTLV) | ||
Experimental Workflow of Probe Capture for Respiratory Syndrome Identification
1. Nucleic Acid Extraction (0.5 h)
2. Library Preparation (2.5 h)
3. Probe Capture (3 h)
4. Sequencing (3 h)
5. Data Analysis
Library–Probe Hybridization 0.5-1 h
*Sequencing duration is calculated based on the GeneMind FASTASeq S series sequencer and SE100 sequencing strategy.
Product Advantages
1. Broad Sample Compatibility, No Pre-Cultivation Required
Supports multiple raw sample types including sewage, human-derived, and environmental samples. Eliminates the need for pre-cultivation and host depletion steps, greatly simplifying the sample preprocessing workflow and significantly improving detection efficiency.
2. Broad Strain Coverage, Complete and Reliable Data
Based on efficient probe hybridization capture and enrichment technology, it enables accurate and unbiased identification and detection of sample genomes.
3. Excellent Sensitivity for Capturing Weak Signals
Addressing the core challenge of low-load infections, probe optimization achieves efficient binding and enrichment of target sequences. Even trace amounts of pathogen nucleic acids can be stably captured, laying a solid foundation for downstream high-sensitivity detection.
4. Rapid and Efficient Hybridization
Powered by TargetSeq® liquid-phase hybridization capture technology, the hybridization between libraries and probes takes only 0.5-1 hour. Combined with fast nucleic acid extraction, library preparation, and sequencing processes, it drastically shortens the detection cycle.
Worry-Free End-to-End Detection
The Respiratory Syndrome Identification Probe Kit has sufficient stock. It is paired with magnetic bead-based extraction kits, RNA pathogen library construction & capture kits, and DNA pathogen library construction & capture kits, enabling seamless connection from sample to data. It supports batch processing with automated liquid handling workstations and is compatible with multiple high-throughput sequencing platforms to meet the needs of various scenarios.
Product Info
Product Name | Speci. | Cat. No |
Respiratory Syndrome Identification Panel | 16 rxn | PH2014801 |
Magnetic Beads Based Pathogen DNA / RNA Co-Extraction Kit | 50 rxn | E10021 |
IGT® RNA Pathogen Microbial Library Prep & Capture Kit(Illumina) | 16rxn | C11371 |
IGT® RNA Pathogen Microbial Library Prep & Capture Kit(MGI) | 16 rxn | C11441 |
IGT-AS12 Automated Liquid Handling Workstation | Configuration III | Q91013 |